Specialty Pharma Journal Specialty, Precision & Technology
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics Inc. announced today that Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients. The licensed TCRm antibodies were developed …
Tag Archives: monoclonal antibodies
July, 2018
March, 2017
-
22 March
Pierre Fabre and H-Immune Partner on Immuno-Oncology Therapeutics
CASTRES and PARIS, France March 21, 2017 – Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, today announced that they have entered into a strategic research partnership which …
July, 2015
-
31 July
Oncobiologics Secures $31 Million to Advance Development of Biosimilars Platform and Pipeline
CRANBURY, N.J., July 27, 2015 /PRNewswire/ — Oncobiologics, Inc., announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive …
April, 2015
-
2 April
Report Forecasts Trends for the World Market of Biosimilar Monoclonal Antibodies through 2025
The overall world biosimilars monoclonal antibodies (mAbs) market is anticipated to rise substantially over the next decade, reaching multibillion dollar annual revenue, according to a new report from Visiongain. With patents for many blockbuster biological drugs expiring, pharmaceutical companies are investing in the development of biosimilars. While biosimilars have been …